The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.
Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.
UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.
Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.
Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.
A new Mayo Clinic study reveals that checkpoint immunotherapy may reorganize the immune environment within lymph nodes after melanoma has spread to them. The research demonstrates how the treatment restructures immune cell interactions in affected lymph nodes.
Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.
Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.
New research published in The Journal of Immunology reveals how high blood sugar and type 1 diabetes may protect against certain cancers including melanoma, breast and colon cancer. The findings could inform development of new cancer immunotherapy treatments by explaining the previously mysterious association between T1D and decreased cancer risk.
Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.
Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.
Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.
Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.
The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.
Caribou Biosciences, a CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, announced it will discontinue its two allogeneic CAR-T cell therapy programs and lay off staff after failing to secure funding for a pivotal lymphoma trial. The company's stock plunged 40% following the announcement as it explores strategic alternatives.
Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.
BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.
Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.
Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.
Researchers at USC have engineered a genetic tool that addresses a major obstacle in cancer immunotherapy by targeting the physical softness of solid tumors, potentially enabling CAR-T cell therapy to work against cancers it previously couldn't treat effectively.
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.
Researchers have developed engineered probiotic bacteria designed to overcome the 'cold' tumor microenvironment in pancreatic cancer, potentially enhancing the effectiveness of immunotherapy treatments for this difficult-to-treat disease.
New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.
Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.
China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.
New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.
Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.
Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.